Oral delivery of ionic complex of ceftriaxone with bile acid derivative in non-human primates.

Ok-Cheol Jeon, Seung Rim Hwang, Taslim A Al-Hilal, Jin Woo Park, Hyun Tae Moon, Seulki Lee, Jae Hyung Park, Youngro Byun

Pharmaceutical research 2013 Apr

filter terms:

Since the absorption of ceftriaxone (CTO) in the intestine is restricted by its natural physiological characteristics, we developed a series of small synthetic compounds derived from bile acids to promote the absorption of CTO in the gastrointestinal tract. Several bile acid derivatives were screened by measuring water solubility and partition coefficient of their complexes with CTO. The pharmacokinetic parameters of the selected CTO/HDCK ionic complex in monkeys were evaluated. The absorption pathway of CTO/HDCK complex was evaluated using Caco-2 cells and MDCK cells transfected with ASBT gene. HDCK enhanced the apparent membrane permeability of CTO 5.8-fold in the parallel artificial membrane permeability assay model. CTO/HDCK complex permeated Caco-2 cell via transcellular pathway, and interaction of the HDCK complex with ASBT was important to enhance uptake. When CTO/HDCK (equivalent to 50 mg/kg of ceftriaxone) formulated with lactose, poloxamer 407 and Labrasol was orally administered to monkeys, its maximum plasma concentration was 19.5 ± 1.8 μg/ml and oral bioavailability 28.5 ± 3.1%. The CTO/HDCK formulation could enhance oral bioavailability of CTO in non-human primates. This oral formulation could be an alternative to injectable CTO with enhanced clinical effects.

Citation

Ok-Cheol Jeon, Seung Rim Hwang, Taslim A Al-Hilal, Jin Woo Park, Hyun Tae Moon, Seulki Lee, Jae Hyung Park, Youngro Byun. Oral delivery of ionic complex of ceftriaxone with bile acid derivative in non-human primates. Pharmaceutical research. 2013 Apr;30(4):959-67